Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...

Clinical Trials

A Study for Tysabri Participant Preference

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS)

Interventions: Drug: Natalizumab

First Posted Date: 2022-03-31

Last Posted Date: 2024-05-17

Lead Sponsor: Biogen

Target Recruit Count: 318

Registration Number: NCT05304520

Locations: 🇩🇪
Katholisches Klinikum Bochum gGmbH, Bochum, Germany
🇩🇪
Neurologie am Mexikoplatz, Berlin, Germany
🇩🇪
Neurologie Neu-Ulm, Neu-Ulm, Germany

and more 37 locations

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Phase 3

Terminated

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Natalizumab

First Posted Date: 2022-03-03

Last Posted Date: 2024-07-05

Lead Sponsor: Biogen

Target Recruit Count: 21

Registration Number: NCT05265728

Locations: 🇯🇵
National Center of Neurology and Psychiatry, Kodaira-shi, Japan
🇯🇵
St.Marianna University Hospital, Kawasaki-shi, Japan
🇯🇵
Chiba University Hospital, Chiba-shi, Japan

and more 9 locations

TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Natalizumab

First Posted Date: 2022-02-11

Last Posted Date: 2024-07-17

Lead Sponsor: Biogen

Target Recruit Count: 600

Registration Number: NCT05236777

Locations: 🇨🇿
Všeobecná fakultní nemocnice v Praze, Prague, Czechia
🇨🇿
Nemocnice Teplice, Teplice, Czechia
🇨🇿
Fakultní nemocnice Brno, Brno, Czechia

and more 12 locations

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BIIB122

First Posted Date: 2022-02-08

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 84

Registration Number: NCT05229562

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Biological: Aducanumab

First Posted Date: 2022-02-01

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 123

Registration Number: NCT05216887

Locations: 🇺🇸
QPS Missouri, Springfield, Missouri, United States
🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
QPS-MRA, Miami, Florida, United States

Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study

Terminated

Conditions: Multiple Sclerosis (MS)

First Posted Date: 2022-01-19

Last Posted Date: 2024-04-17

Lead Sponsor: Biogen

Target Recruit Count: 160

Registration Number: NCT05197699

Locations: 🇩🇪
Multiple Sklerose Zentrum, Bamberg, Germany
🇩🇪
Universitätsklinikum Tübingen, Neurologie, Tübingen, Germany
🇩🇪
St. Josef Hospital, Klinikum der Ruhr-Universität Bochum, Bochum, Germany

and more 9 locations

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BIIB113
Drug: BIIB113-Matching Placebo
Drug: 11^C]BIO-1819578

First Posted Date: 2022-01-18

Last Posted Date: 2024-02-05

Lead Sponsor: Biogen

Target Recruit Count: 72

Registration Number: NCT05195008

Locations: 🇬🇧
Medicines Evaluation Unit, Wythenshawe, Manchester, United Kingdom
🇸🇪
Karolinska Comprehensive Cancer Center - Studieenheten, Flemingsberg, Stockholm, Sweden
🇬🇧
Hammersmith Medicine Research, London, Brent, United Kingdom

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

Phase 1

Terminated

Conditions: Spinocerebellar Ataxia Type 3

Interventions: Drug: BIIB132
Drug: BIIB132-Matching Placebo

First Posted Date: 2021-12-16

Last Posted Date: 2023-08-04

Lead Sponsor: Biogen

Target Recruit Count: 8

Registration Number: NCT05160558

Locations: 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸
University of Florida, Center for Movement Disorders, Gainesville, Florida, United States
🇵🇹
Centro Hospitalar do Porto, Porto, Portugal

and more 17 locations

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BIIB104 Test Formulation
Drug: BIIB104 Reference Formulation

First Posted Date: 2021-12-09

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 36

Registration Number: NCT05152485

Locations: 🇺🇸
QPS MRA, Miami, Florida, United States

A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BIIB104
Drug: Placebo

First Posted Date: 2021-12-08

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 31

Registration Number: NCT05148481

Locations: 🇺🇸
Research Site, Anaheim, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy